Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master Protocol for Phase 1 Trials of Amyloid-Targeting Therapies in Alzheimer's Disease
NCT07787169Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 3
01
Overview
Phase 1, randomised trial of LY4405094 in Alzheimer's disease (AD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants allocated to each substudy at Day 160. Started Sep 2026; status: recruiting.
02
Drugs
LY4405094
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07787169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787169.